Found 13614 matches for
Professor Paul Riley will lead the scientific vision of the first institute of its kind in the world to physically merge the disciplines of developmental biology and regenerative medicine in a common goal to treat some of the world’s most prolific diseases.
Led by Prof Paul Riley, to understand the underlying biology of cardiovascular development, develop novel models of congenital heart disease and to explore ways in which developmental processes can be harnessed to promote heart regeneration and repair.
Led by Prof Sir Rory Collins, incorporates population health sciences and new developments in Oxford’s Big Data Institute with contributions in image analysis, bioengineering, genetic and biomarker approaches in complex traits.
Led by Prof Hugh Watkins, to span inherited diseases (gene discovery, phenotyping, disease mechanisms and clinical application of genetic testing) through to post-GWAS functional analyses, including model organism and cell biology approaches aiming to extract biological insight from genetically validated mechanisms.
Led by Prof Keith Channon, will incorporate the best of our hypothesis driven, disease mechanism research where efforts are specifically targeted to discovery of tractable targets and medicinal chemistry approaches (existing partnerships with Chemistry and the Target Discovery Institute and new links with the Structural Genomics Consortium and the Interdisciplinary Science building).
Aim: to continue to discover rare, large-effect, genetic variants with which to dissect heart muscle disease and cardiac development, and to uncover susceptibility variants to implicate new processes in vascular disease.
This theme covers the two major areas of work outlined below.
Research on normal heart development, mechanisms underlying congenital heart disease and the potential for applying developmental processes to adult cardiovascular repair.
Employing a computational strategy to translate basic science to personalised application.
Aim: to focus expertise in drug discovery and pharmacology on the cardiovascular system through synergistic interactions between chemists, pharmacologists, cardiovascular scientists and computational biologists.
The cross-cutting theme of imaging has an important integrating role across the CRE programme, with physicists and bioengineers working alongside biomedical researchers.
Reliable assessment of the treatment and prevention of cardiovascular disease
Reliable assessment of the main determinants of cardiovascular disease
(Inflammatory cells, fibroblasts)
(Identification, characterisation and recruitment)
(Differentiation and functional maturation)